Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval.

Recently, several drugs for non-cardiovascular diseases have ceased marketing because of cardiovascular risk, highlighting the importance of evaluating the cardiovascular safety of new drugs even if not intended for cardiovascular diseases. Assessing and ensuring acceptable cardiovascular safety of non-cardiovascular drugs is difficult; nonetheless, governmental regulatory agencies are likely to change the requirements for drug safety information. This article explores our recommendations for rethinking current regulatory policies, emphasizing the need for mandatory post-marketing surveillance registries and highlighting the exposures necessary to subserve the need for greater assessment of safety issues.

[1]  J. Manson,et al.  Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and the Risk of Cardiovascular Events , 2006, Circulation.

[2]  R. Lewis,et al.  Risk assessment in drug development for symptomatic indications: A framework for the prospective exclusion of unacceptable cardiovascular risk , 2006, Clinical pharmacology and therapeutics.

[3]  Daniel M. Hartung,et al.  Risk of Hospitalization for Heart Failure Associated with Thiazolidinedione Therapy: A Medicaid Claims–Based Case‐Control Study , 2005, Pharmacotherapy.

[4]  S. Frantz.  Drug safety special: Chasing shadows , 2005, Nature.

[5]  M. Wadman.  Drug safety special: The safety catch , 2005, Nature.

[6]  Robert Riddell,et al.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.

[7]  B. Psaty,et al.  COX-2 inhibitors--lessons in drug safety. , 2005, The New England journal of medicine.

[8]  Andreas Hoeft,et al.  Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. , 2005, The New England journal of medicine.

[9]  Marc A Pfeffer,et al.  Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention , 2005, The New England journal of medicine.

[10]  Ronnie Driver,et al.  Biostatistics: a Methodology for the Health Sciences , 2005 .

[11]  J. Couzin.  FDA Panel Urges Caution on Many Anti-Inflammatory Drugs , 2005, Science.

[12]  S. Shoor,et al.  Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study , 2005, The Lancet.

[13]  J. Couzin.  Drug safety. FDA panel urges caution on many anti-inflammatory drugs. , 2005, Science.

[14]  Jennifer Couzin,et al.  Withdrawal of Vioxx Casts a Shadow Over COX-2 Inhibitors , 2004, Science.

[15]  John Sharkey,et al.  Acquired QT interval prolongation and HERG: implications for drug discovery and development. , 2004, European journal of pharmacology.

[16]  T. Elasy,et al.  Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association: response to Nesto. , 2004, Diabetes care.

[17]  J. Couzin.  Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. , 2004, Science.

[18]  R. Makuch,et al.  Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. , 2003, The American journal of cardiology.

[19]  M. Braun,et al.  Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist , 2003, Annals of Internal Medicine.

[20]  A. Camm,et al.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.

[21]  S. Grundy,et al.  Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. , 2003, Circulation.

[22]  P. Bacchetti,et al.  Sample size calculations in clinical research. , 2002, Anesthesiology.

[23]  V. Rigolin,et al.  Appetite suppressants and valvular heart disease. , 2002, Current opinion in cardiology.

[24]  W. Ray,et al.  Non-steroidal antiinflammatory drugs and risk of serious coronary heart disease , 2002, The Lancet.

[25]  C Michael Stein,et al.  Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study , 2002, The Lancet.

[26]  D. Bloomfield,et al.  The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Step 5 NOTE FOR GUIDANCE ON THE CLINICAL EVALUATION OF QT/QTc INTERVAL PROLONGATION AND PROARRHYTHMIC POTENTIAL FOR NON- ANTIARRHYTHMIC DRUGS (CHMP/ICH/2/04) TRANSMISSION TO CHMP , 2002 .

[27]  D. Wysowski,et al.  Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and food and drug administration regulatory actions , 2001, American Journal of Gastroenterology.

[28]  J. Woodcock,et al.  The safety of newly approved medicines: do recent market removals mean there is a problem? , 1999, JAMA.

[29]  J. Vessey,et al.  The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. , 1998, The New England journal of medicine.

[30]  L. Weinrauch,et al.  A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. , 1998, The New England journal of medicine.

[31]  E. Mark,et al.  Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. , 1997, The New England journal of medicine.

[32]  B. Corya,et al.  Valvular heart disease associated with fenfluramine-phentermine. , 1997, The New England journal of medicine.

[33]  Tau Fluvalinate,et al.  The European Agency for the Evaluation of Medicinal Products , 1997 .

[34]  L. Fisher,et al.  Biostatistics: A Methodology for the Health Sciences , 1993 .

[35]  D. Wortham,et al.  Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. , 1993, JAMA.

[36]  R. Woosley,et al.  Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin , 1992, Clinical pharmacology and therapeutics.

[37]  Ira R. Weiss,et al.  Issues and opportunities , 1988, DATB.